Testing the Combination of APG-1252 (Pelcitoclax) and Cobimetinib in Recurrent Ovarian and Endometrial Cancers
Testing the Combination of APG-1252 (Pelcitoclax) and Cobimetinib in Recurrent Ovarian and Endometrial Cancers
Active, not recruiting · NCT05691504 · Registry updated 2026-10-09Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Testing the Combination of APG-1252 (Pelcitoclax) and Cobimetinib in Recurrent Ovarian and Endometrial Cancers | Adnexal Diseases, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Genital Diseases, Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Connective and Soft Tissue, Urogenital Diseases, Urogenital Neoplasms, carcinosarcoma, endometrium neoplasm, fallopian tube disorder, fallopian tube neoplasm, female reproductive system disorder, female reproductive system neoplasm, mixed neoplasm, neoplasm, sarcoma, uterine disorder | Active, not recruiting | Phase 1 | 2026-10-09 | NCT05691504 |
1 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| National Cancer Institute (NCI) | 3015 |
6 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Dana-Farber Cancer Institute | Boston | United States | 626 |
| Emory University Hospital/Winship Cancer Institute | Atlanta | United States | 299 |
| Johns Hopkins University/Sidney Kimmel Cancer Center | Baltimore | United States | 238 |
| National Cancer Institute Developmental Therapeutics Clinic | Bethesda | United States | 28 |
| National Institutes of Health Clinical Center | Bethesda | United States | 800 |
| Rutgers Cancer Institute of New Jersey | New Brunswick | United States | 223 |